Naputinib tosilate

N/A

Report date: 2026/05/08 20:02:52
NME

Base Information

Drug NameNaputinib tosilate
Drug Alias Namenaputinib tosilatenaiputiniNEP-015
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionEpidermal growth factor receptor erbB1 inhibitors
TargetsEpidermal growth factor receptor erbB1
Therapy Area/IndicationsSolid tumoursCarcinoma, Non-Small-Cell Lung
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPreclinical
Originator CompaniesShenzhen Neptunus Bioengineering Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesShenzhen Neptunus Bioengineering Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumoursCarcinoma, Non-Small-Cell Lung
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A